Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study

Published:2023-11-21 Issue:1 Volume:41 Page:391-412
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Lu Kepeng,Liao Qian-Qian,Zhu Ke-Wei^ORCID,Yao Ying,Cui Xiao-Jiao^ORCID,Chen Peng,Bi Ying,Zhong Meng,Zhang Hao,Tang Jing-Cai,Yu Qin,Yue Jia-Kui,He Hui,Zhu Ze-Feng^ORCID,Cai Ze-Zheng,Yang Zhe,Zhang Wei,Dong Yang-Tao,Wei Qiu-Mian,He Xuegai

Funder

Health Commission of Henan Province

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02717-5.pdf

Reference39 articles.

1. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398(10294):64–77.

2. Zhang X, Cai Q, Wang X, et al. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis. 2021;52(3):863–71.

3. Ajmal M, Friedman J, Sipra Q, Lassar T. Rivaroxaban: expanded role in cardiovascular disease management—a literature review. Cardiovasc Ther. 2021;2021:8886210.

4. Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban—metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636–42.

5. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18–27.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), and Eosinophil-to-Lymphocyte Ratio (ELR) as Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD);International Journal of Chronic Obstructive Pulmonary Disease;2024-02